Kazia Therapeutics (KZIA) AI Stock Analysis

• Market Cap: $73.00M
• Dividend Yield: N/A
• Average Volume (3M): 209.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: -98.25%
• EPS Growth: 63.05%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 11,335,992
• 10 Day Avg. Volume: 60,839
• 30 Day Avg. Volume: 209,481
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.13
• Enterprise Value/Revenue: 3.69
• Enterprise Value/Gross Profit: 3.69
• Enterprise Value/Ebitda: -0.34
• 1Y Price Target: $19.00
• Price Target Upside: 195.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $6.00 ▼(-6.83% Downside)

The score is primarily constrained by weak financial performance (minimal revenue, large ongoing losses, and sustained cash burn with negative equity). Technicals also weigh negatively due to a clear downtrend and bearish momentum, with only a near-oversold setup offering limited offset. Valuation provides little support because profitability is negative and there is no dividend yield data.

Positive Factors

Innovative Oncology Focus

Kazia's focus on developing novel cancer therapeutics, particularly for aggressive forms like glioblastoma, positions it well in a high-demand market, potentially leading to significant breakthroughs and partnerships.

Strategic Partnerships

Strategic partnerships enhance Kazia's research capabilities and provide funding, which is vital for advancing clinical trials and increasing the likelihood of successful drug commercialization.

Pipeline Potential

Paxalisib's development for glioblastoma addresses unmet medical needs, offering potential for significant impact in oncology treatment and future revenue streams upon successful trials and approval.

Negative Factors

Financial Instability

The company's financial instability, marked by negative equity and cash flow issues, threatens its operational sustainability and ability to fund ongoing research without external investment.

Negative Cash Flow

Negative cash flow indicates Kazia is not generating enough cash from operations, which could hinder its ability to cover expenses and invest in R&D, necessitating reliance on external financing.

Declining Revenue

Declining revenue reflects challenges in commercializing products and achieving growth, which could impact long-term viability and investor confidence if not addressed.

Kazia Therapeutics Business Overview & Revenue Model

Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

How the Company Makes Money

Kazia Therapeutics primarily generates revenue through the development and potential commercialization of its drug candidates. The company seeks to advance its therapies through clinical trials and, upon successful results and regulatory approval, aims to license its drugs to larger pharmaceutical companies or bring them to market directly. Key revenue streams include milestone payments, royalties from licensing agreements, and potential sales revenue of approved drugs. Partnerships with research institutions and pharmaceutical companies also play a crucial role in funding and advancing their drug development programs.

Kazia Therapeutics Financial Statement Overview

Summary

Financials are weak: revenue is extremely small and fell sharply (~$42K in 2025 vs. ~$2.3M in 2024), losses remain large (net loss ~-$20.7M in 2025), and operating/free cash flow are persistently negative (FCF ~-$13.3M in 2025). Low absolute debt helps, but negative equity and a shrinking asset base signal elevated funding and execution risk.

Income Statement

The revenue base is extremely small and volatile, with annual revenue dropping to ~$42K in 2025 from ~$2.3M in 2024 (sharp contraction after a prior spike). Profitability remains deeply negative: EBIT and net income are consistently large losses (e.g., net loss of ~$20.7M in 2025 and ~$26.8M in 2024), indicating ongoing high operating spend relative to revenue. A key positive is that gross profit equals revenue in the periods shown, but the business is still far from covering operating costs.

Balance Sheet

Leverage is low in absolute terms (total debt ~ $0.4M in 2025, down from ~$0.6M in 2024), which reduces near-term balance sheet risk from creditors. However, equity has turned negative (stockholders’ equity of about -$8.3M in 2025 and -$10.0M in 2024), which is a meaningful weakness and reflects accumulated losses and capital erosion. Total assets also fell materially (to ~$6.1M in 2025 from ~$21.6M in 2024), pointing to a shrinking balance sheet and potentially reduced financial flexibility.

Cash Flow

Cash generation remains a clear weakness: operating cash flow and free cash flow are consistently negative across all years shown, including about -$13.3M in 2025 and -$9.6M in 2024, implying continued cash burn to fund operations. Free cash flow improved versus 2024 (as indicated by positive free cash flow growth in 2025), but the company is still reliant on external funding to sustain operations. The pattern over multiple years suggests limited self-funding capacity until revenue scales materially or costs are reduced.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	2.50M	―	42.00K	2.31M	555.00	10.00K
Gross Profit	2.50M	―	42.00K	2.31M	555.00	10.00K
EBITDA	-27.08M	―	-13.28M	-26.59M	-22.28M	-23.52M
Net Income	-28.41M	―	-20.70M	-26.78M	-20.47M	-25.01M
Balance Sheet
Total Assets	17.91M	―	6.06M	21.59M	28.08M	35.89M
Cash, Cash Equivalents and Short-Term Investments	3.06M	―	4.34M	1.66M	5.24M	7.36M
Total Debt	140.74K	―	396.00K	634.00K	1.80M	1.84M
Total Liabilities	21.72M	―	14.36M	31.60M	16.03M	17.61M
Stockholders Equity	-3.81M	―	-8.30M	-10.02M	12.05M	18.27M
Cash Flow
Free Cash Flow	-7.46M	―	-13.28M	-9.58M	-15.16M	-22.76M
Operating Cash Flow	-7.46M	―	-13.28M	-9.58M	-15.16M	-22.76M
Investing Cash Flow	0.00	―	0.00	0.00	0.00	-2.37M
Financing Cash Flow	5.49M	―	15.98M	5.99M	12.97M	3.73M

Kazia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Negative. The current price of 6.44 is below the 20-day moving average (MA) of 7.67, below the 50-day MA of 8.82, and below the 200-day MA of 7.12, indicating a bearish trend. The MACD of -0.97 indicates Positive momentum. The RSI at 41.04 is Neutral, neither overbought nor oversold. The STOCH value of 67.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KZIA.

Kazia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLTO	52 Neutral	$34.85M	-1.93	-114.81%	―	―	37.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRKR	49 Neutral	$30.51M	-1.39	-110.67%	―	-12.99%	-13.67%
PHIO	46 Neutral	$12.81M	-0.53	-107.58%	―	―	83.95%
RNAZ	44 Neutral	$7.29M	-0.04	-1763.01%	―	―	96.75%
KZIA	41 Neutral	$73.00M	-0.51	―	―	-98.25%	63.05%
XTLB	39 Underperform	$6.62M	-9.56	―	―	―	65.45%

Kazia Therapeutics Corporate Events

Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance

On December 18, 2025, Kazia Therapeutics Limited regained compliance with Nasdaq’s continued listing standards by meeting the alternative minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1), after previously being notified on November 12, 2025 that it had failed to satisfy the $35 million market value of listed securities threshold by November 10, 2025. As a result, a Nasdaq hearing that had been scheduled for January 8, 2026 to address potential suspension or delisting was cancelled, and Nasdaq confirmed that Kazia’s ADSs will continue trading on the Nasdaq Capital Market, removing an immediate overhang of listing risk for the company and its investors.

The most recent analyst rating on (KZIA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium

On December 10, 2025, Kazia Therapeutics announced promising new data from the San Antonio Breast Cancer Symposium regarding their drug paxalisib. The findings demonstrate paxalisib’s ability to reinvigorate anti-tumor immunity in advanced breast cancer populations, including TNBC and HER2+. The data, derived from advanced liquid biopsy profiling and immune phenotyping, suggest that paxalisib can disrupt aggressive circulating tumor cell clusters and enhance responsiveness to immunotherapy. This positions paxalisib as a potentially transformative agent in breast cancer treatment, offering new therapeutic opportunities beyond current HER2-targeted therapies and checkpoint inhibitors.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance

On December 2, 2025, Kazia Therapeutics Limited entered into Securities Purchase Agreements with institutional and accredited purchasers for a private placement of equity securities, raising approximately $46.5 million. This financial move was aimed at addressing the company’s compliance with Nasdaq’s listing standards, following a staff determination letter received on November 12, 2025, indicating the company’s market value was below the required minimum. The successful private placement is expected to enhance Kazia’s stockholders’ equity, potentially aiding in regaining compliance with Nasdaq’s requirements, although there is no guarantee of the outcome.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development

On December 2, 2025, Kazia Therapeutics announced a $50 million private placement of equity securities with institutional and accredited investors, expected to close by December 3, 2025. The net proceeds of approximately $46.5 million will be used to further clinical development of their lead program, paxalisib, and other corporate purposes, extending the company’s cash runway into the second half of 2028. This strategic financial move is set to bolster Kazia’s position in the oncology drug development sector, supporting its ongoing trials and potential market expansion.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline

Kazia Therapeutics Limited announced that it received a staff determination letter from Nasdaq on November 12, 2025, indicating the company had not regained compliance with the Market Value of Listed Securities requirement by the deadline of November 10, 2025. As a result, Kazia plans to request a hearing before a Nasdaq Hearings Panel to demonstrate its ability to meet the listing criteria and sustain long-term compliance. The outcome of this hearing is uncertain, and the company’s securities face potential suspension or delisting from the Nasdaq Capital Market.

The most recent analyst rating on (KZIA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.